Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Anticoagulants

Apixaban more effective than warfarin regardless of polypharmacy

Researchers found new anticoagulant consistently reduced stroke, although benefits for major bleeding risk declined as number of medicines increased.

The oral anticoagulant apixaban is consistently more effective than warfarin for patients with atrial fibrillation regardless of the number of other drugs they take, a study has found. 

Apixaban (Eliquis; Bristol-Myers Squibb) is a new oral anticoagulant used to reduce the risk of stroke. While studies have found it to be more effective and safer than warfarin, it has been unclear whether this was the case in patients taking many medications. 

Reporting their findings in The BMJ[1] (online, 20 June 2016), researchers re-analysed data from the Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, where 18,201 patients were randomised to either apixaban or warfarin. Patients were split into one of three groups according to the number of medicines they took at baseline: 0–5 medicines, 6–8 medicines or ≥9 medicines. Polypharmacy was observed in 13,932 patients (76.5%), which is defined as taking more than five medicines. 

The authors discovered that, while apixaban consistently reduced the risk of stroke or systemic embolism compared to warfarin for all medication groups, the benefit of apixaban over warfarin with regards to major bleeding risk declined as the number of medicines increased. 

The absolute rate reduction of major bleeding per 100 patient years was 1.28, 0.82, and 0.66 for the three groups (0–5, 6–8, and ≥9 drugs, respectively). Interestingly, the researchers note that the decline in benefit did not seem to be the result of patients taking interacting medicines that enhance anticoagulation. 

The risk of death increased significantly with increasing medication burden (P<0.001) as did the risk of stroke and systemic embolism (1.29, 1.48, and 1.57 per 100 patient years, for 0–5, 6–8, and ≥9 drugs, respectively). The risk of major bleeding also increased with the number of medicines taken (1.91, 2.46, and 3.88 per 100 patient years, respectively). As expected, the researchers found that the more health conditions a patient had, the more medicines they were prescribed and they say that the increase in health risk must be placed in the context of the increasing burden of illnesses, not just an increasing number of medications. 

Sharron Gordon

Source: Sharron Gordon

Sharron Gordon, a consultant pharmacist in coagulation, says the results should be used as an opportunity to minimise risks by stopping other medicines that may no longer be required

Commenting on the study, Sharron Gordon, consultant pharmacist in anticoagulation at the Hampshire Hospitals NHS Foundation Trust, says the results will come as no surprise to pharmacists, who are always aware of concomitant medicines, but that this should not detract from the need to anticoagulate patients. 

“This must be used as an opportunity to minimise risks by stopping other medicines that may no longer be required, particularly antiplatelets and other interacting or potentiating medicines,” she says. 

She warns drawing any firm conclusions from a post-hoc review is not recommended because the study was “not powered to generate these findings”. 

In addition, Gordon points out that the trial had a patient demographic of reasonably low-risk patients who had relatively low scores on an assessment of both stroke risk and major bleeding risk, plus average follow-up was only 1.8 years. “In real life situations these outcomes could be different,” she says. 

Of note in the multi-region trial, which involved patients from North and Latin America, Europe and Asia, was that patients in the United States and Canada were prescribed many more medicines than those in other regions: 53% of US patients and 38% of Canadian patients were taking nine or more medicines, compared with 10–21% in other regions. 

The researchers say that although patients in the United States had more comorbidities than those in other regions, a greater number of drugs were used in US patients regardless of comorbidities.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201348

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Blood clot illustration
  • Sharron Gordon

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.